Event-Driven Stocks

Tvardi Therapeutics, Inc.

TVRDNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue—$7.1M$21.0M$41.9M$23.0M$135.1M
Operating income−$26.7M−$58.4M−$121.5M−$87.5M−$89.1M$5.4M
Net income−$18.2M−$70.9M−$118.5M−$85.5M−$88.4M$8.4M
Total assets$32.1M$43.8M$125.8M$182.2M$247.1M$271.2M
Total liabilities$11.1M$48.4M$68.8M$23.5M——
Equity$20.9M−$4.6M$57.1M$158.8M$227.5M$249.0M
EPS (diluted)$-3.26$-15.53$-26.26$-19.12$-1.74$0.18
Shares out.4.6M54.7M53.9M53.5M49.9M46.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−87.0%
Return on assets
−56.8%
Return on capital (ROCE)
−127.2%
Liabilities / assets
34.7%
Debt / equity
0.53×
Book value / share
$4.58
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-10.66distress
Accruals / assets
16.5%high accruals
Piotroski F-Score
3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
36
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 2 warning● 1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026490,17011.1-3.7%
Apr 30, 2026508,94114.8-8.2%
Apr 15, 2026554,3428.1-15.2%
Mar 31, 2026653,88213.4-2.2%
Mar 13, 2026668,56616.1+5.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.